A Phase 1/2 interventional study of CC-99282 and Rituximab in Lymphoma, Non-Hodgkin, sponsored by Celgene. Active, not recruiting at 66 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-19.
Sponsored by Celgene · Phase 1/2, Interventional, and Treatment
The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of CC-99282 alone and in combination with anti-lymphoma agents in participants with relapsed or refractory non-Hodgkin's lymphomas.
Participants with relapsed or refractory non-Hodgkin's lymphomas (R/R NHL) who have failed at least 2 lines of therapy (or have received at least one prior line of standard therapy and are not eligible for any other therapy).
The dose escalation will evaluate the safety and tolerability of escalating doses of CC-99282 in relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) and/or relapsed or refractory follicular lymphoma (R/R FL) participants to determine the maximum tolerated dose (MTD) of CC-99282 as monotherapy.
The dose expansion will further evaluate the safety and preliminary efficacy of single agent CC-99282 or the safety and preliminary efficacy of CC-99282 in combination with anti-lymphoma agents in participants with R/R DLBCL and NHL.
Part B Cohort B will further evaluate the potential effects of food on the PK and safety of CC-99282.
1,989 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 307 are open to participants now.
This study's planned enrollment of 438 is above the median of 41 across 1,703 interventional studies indexed under Lymphoma, Non-Hodgkin.
Browse Lymphoma, Non-Hodgkin studies →Celgene is the lead sponsor of 419 studies on the registry; 13 are open to participants now.
Of its 100 completed or terminated interventional studies of FDA-regulated products, 29 (29%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria
Drug: CC-99282
Drug: CC-99282 · Drug: Rituximab · Drug: Obinutuzumab · Drug: Tafasitamab · Drug: Valemetostat
Specified dose on specified days
Also known as: BMS-986369
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
Incidence of Adverse Events (AEs)
Time frame: From the time of consent at screening until 28 days after the subject discontinued study treatment (up to 4 years)
Number of participants with laboratory abnormalities
Time frame: From the time of consent at screening until 28 days after the subject discontinued study treatment (up to 4 years)
Number of participants with vital sign abnormalities
Time frame: From the time of consent at screening until 28 days after the subject discontinued study treatment (up to 4 years)
Number of participants with electrocardiogram (ECG) abnormalities
Time frame: From the time of consent at screening until 28 days after the subject discontinued study treatment (up to 4 years)
Number of participants with Eastern Cooperative Oncology Group (ECOG) performance status abnormalities
Time frame: From the time of consent at screening until 28 days after the subject discontinued study treatment (up to 4 years)
Number of participants with left ventricular ejection fraction (LVEF) assessment abnormalities
Time frame: From the time of consent at screening until 28 days after the subject discontinued study treatment (up to 4 years)
Number of participants with physical examination abnormalities
Time frame: From the time of consent at screening until 28 days after the subject discontinued study treatment (up to 4 years)
Dose Limiting Toxicity (DLT)
Time frame: Up to 28 days in Cycle 1
Maximum tolerated dose (MTD)
Time frame: Up to 28 days in cycle 1
Pharmacokinetics - Maximum plasma concentration of drug (Cmax)
Time frame: Cycle 1 to Cycle 4 Day 15 (each cycle is 28 days)
Pharmacokinetics - Area under the plasma concentration-time curve (AUC)
Time frame: Cycle 1 to Cycle 4 Day 15 (each cycle is 28 days)
Pharmacokinetics - Time to peak (maximum) plasma concentration (Tmax)
Time frame: Cycle 1 to Cycle 4 Day 15 (each cycle is 28 days)
Pharmacokinetics - Terminal-phase elimination half-life (T-HALF)
Time frame: Cycle 1 to Cycle 4 Day 15 (each cycle is 28 days)
Pharmacokinetics - Apparent total body clearance of the drug from the plasma (CLT/F)
Time frame: Cycle 1 to Cycle 4 Day 15 (each cycle is 28 days)
Pharmacokinetics: Apparent volume of distribution (Vz/F)
Time frame: Cycle 1 to Cycle 4 Day 15 (each cycle is 28 days)
Objective response rate (ORR)
Defined as the percent of subjects whose best response is Complete Response (CR) or Partial Response (PR). Determined by the Lugano Classification for NHL response criteria
Time frame: Up to approximately 6 years
Time to response (TTR)
Determined by the Lugano Classification for NHL response criteria
Time frame: Up to approximately 6 years
Duration of response (DoR)
Determined by the Lugano Classification for NHL response criteria
Time frame: Up to approximately 6 years
Progression free survival (PFS)
Time from first dose of CC-99282 to the first occurrence of disease progression or death from any cause Determined by the Lugano Classification for NHL response criteria
Time frame: Up to approximately 6 years
Overall survival (OS)
Time from first dose of CC-99282 to death from any cause Determined by the Lugano Classification for NHL response criteria
Time frame: Up to approximately 6 years
ORR
Defined as the percent of subjects whose best response is Complete Response (CR) or Partial Response (PR). Determined using the modified International PCNSL Collaborative Group (IPCG) criteria
Time frame: Up to approximately 4 years
TTR
Determined using the modified International PCNSL Collaborative Group (IPCG) criteria
Time frame: Up to approximately 4 years
DOR
Determined using the modified International PCNSL Collaborative Group (IPCG) criteria
Time frame: Up to approximately 4 years
PFS
Determined using the modified International PCNSL Collaborative Group (IPCG) criteria
Time frame: Up to approximately 4 years
OS
Determined using the modified International PCNSL Collaborative Group (IPCG) criteria
Time frame: Up to approximately 4 years
Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html
Supporting information: Study protocol, Sap, Csr
This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Celgene